Literature DB >> 375948

The antithrombotic activity of BAY g 6575.

F Seuter, W D Busse, K Meng, F Hoffmeister, E Möller, H Horstmann.   

Abstract

The activity of 1-[2-(beta-naphthyloxy)ethyl]-3-methyl-2-pyrazolin-5-one (= BAY g 6575) was evaluated in models of experimental thrombosis caused by traumatically induced damage of vessel segments. After prophylactic administration of BAY g 6575 (0.3 mg/kg p.o.) to rats the thrombus formation was significantly reduced in the carotid artery as well as in the jugular vein. The thrombus formation in the femoral arteries of rabbits is inhibited at a minimal effective dose of 1 mg/kg p.o. The incidence of occlusive thrombi is not influenced. BAY g 6575 is 10 times more potent than acetylsalicylic acid (ASA). In the arterial system the thrombus formation is frequently completely abolished.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 375948

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

1.  Oral nafazatrom in man: effect on inhaled antigen challenge.

Authors:  R W Fuller; N Maltby; R Richmond; C T Dollery; G W Taylor; W Ritter; E Philipp
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

2.  Phase I and pharmacologic evaluation of nafazatrom in patients with cancer.

Authors:  C D Haas; L H Baker; L J Evans
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  [Evolution in the early changes in the establishment of arterial thrombi (author's transl)].

Authors:  W Hofmann; T Rommel; T Schaupp; F Seuter; J A Rossner; F M Hecht; G Mall
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

4.  Effect of nafazatrom and indomethacin on pulmonary removal of prostaglandin E1 after endotoxin in rabbits.

Authors:  C N Gillis; A M Havill; R Moalli
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

5.  Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies.

Authors:  C D Haas; G W Kyle; J D Crissman; M F Schaldenbrand
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

6.  The effects of oral nafazatrom (= BAY g 6575) on canine coronary artery thrombosis and myocardial ischemia.

Authors:  V B Fiedler
Journal:  Basic Res Cardiol       Date:  1983 May-Jun       Impact factor: 17.165

7.  Phase I clinical study of nafazatrom.

Authors:  G N Hortobagyi; N E Papadoupoulos; D Frye; J Ajani; J M Reuben
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

8.  Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system.

Authors:  K V Honn
Journal:  Clin Exp Metastasis       Date:  1983 Apr-Jun       Impact factor: 5.150

9.  The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.

Authors:  V B Fiedler; M Mardin; E Perzborn; R Grützmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.